CD274 and neoplasm: The first results were recently released and even if the OS data are not yet mature (median survival follow-up was 15 months), the PFS in ITT patients with PD-L1+ tumour was 11.2 months versus 8.4 months (HR = 0.74; 98.5% CI, 0.57 to 0.96; p = 0.02), which is comparable with PFS in IIT patients irrespective of PD-L1 expression (11.2 months versus 8.4 months), with acceptable safety.